Drug intelligence / Profile preview

NV103

Development stage: Preclinical
Lead developer: NanoValent Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**NV103** is an investigational antibody-drug conjugate nanoparticle utilizing NanoValent Pharmaceuticals' proprietary NanoMod™ platform, featuring an anti-CD99 antibody conjugated to liposomal irinotecan for targeted delivery to CD99-positive tumors. It aims to enhance efficacy and reduce systemic toxicity of irinotecan, a topoisomerase I inhibitor, by selectively accumulating in tumor cells expressing CD99, a cell surface antigen overexpressed in certain pediatric and aggressive cancers. Developed in collaboration with Children's Hospital Los Angeles, NV103 is in advanced preclinical development with GMP validation underway for IND-enabling toxicology studies to support Phase 1/2 trials, primarily targeting Ewing sarcoma but with potential expansion to hepatocellular carcinoma, leukemia, neuroendocrine tumors, glioblastoma, and acute myeloid/lymphoblastic leukemia.[1][3][4][7][11]

Other names: antiCD99 TNS (CD99TNS/Ir)CD99/Irinotecan nanoparticlesAntibody-conjugated irinotecan liposomal nanoparticle

Targets

TOP1 (DNA Topoisomerase I)CD99 (CD99 molecule)

Beyond the preview

Go deeper on NV103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV103.

Explore the full profile